AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2026
Feb 4, 2026
32312_dirs_2026-02-04_378fc673-eb3c-4a6a-9f03-24f78c98f165.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2026-02-03
Reporting Person: Schoenberg Mark (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-03 | Ordinary Shares | S | 1844 | $19.69 | Disposed | 150514 | Direct |
| 2026-02-03 | Ordinary Shares | S | 1843 | $19.69 | Disposed | 148671 | Direct |
| 2026-02-03 | Ordinary Shares | S | 3686 | $19.69 | Disposed | 144985 | Direct |
Footnotes
F1: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
More from UroGen Pharma Ltd.
Annual Report
2026
May 27
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11